Dosage & Administration
Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
The flm-coated tablets must be taken orally, swallowed with a sufcient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.
Anti-epileptic drugs: pre-market data from adult clinical studies indicate that levetiracetam does not affect existing anti-epileptic drugs (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidium) Ketones), and these anti-epileptic drugs have no effect. Affect the pharmacokinetics of levetiracetam.
Probenecid: Probenecid (500 mg, 4 times a day) is a renal tubular secretion blocker that has been shown to inhibit the renal clearance of major metabolites, but does not inhibit the renal clearance of levetiracetam . However, the concentration of this metabolite is still very low.
Methotrexate: It is reported that taking levetiracetam and methotrexate at the same time will reduce the clearance rate of methotrexate, causing the concentration of methotrexate in the blood to increase/extend to potentially toxic levels. For patients treated with these two drugs at the same time, the blood concentrations of methotrexate and levetiracetam should be carefully monitored.
Laxatives: When the osmotic laxative polyethylene glycol is co-administered with oral levetiracetam, isolated cases of reduced efficacy of levetiracetam have been reported. Therefore, polyethylene glycol should not be taken orally within one hour before and one hour after taking levetiracetam.
Food and alcohol: The absorption of levetiracetam is not affected by food, but the absorption rate is slightly reduced. There is no data on the interaction of levetiracetam with alcohol.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.
The following are the most common adverse responses (incidence 5% higher than placebo):
Pregnancy & Lactation
Levetiracetam should not be used during pregnancy or by women of reproductive potential who are not utilizing contraception unless it is clinically essential. Human breast milk contains levetiracetam. As a result, nursing is not advised. If levetiracetam medication is required while breastfeeding, the treatment's value and risk should be evaluated against the importance of breastfeeding. In animal trials, there was no effect on fertility. There are no clinical data available, and the risk to humans is unclear.
Precautions & Warnings
Kidney damage: Patients with kidney damage may need to adjust the dose when taking levetiracetam. For patients with severe hepatic impairment, it is recommended to assess kidney function before choosing a dose.
Acute kidney injury: Levetiracetam use is rarely associated with acute kidney injury, and the time of onset varies from a few days to a few months.
Blood cell count: Rare reductions in blood cell count (neutropenia, agranulocytosis, leukopenia, thrombocytopenia and pancytopenia) are related to the administration of levetiracetam, usually at the beginning of treatment. For patients with severe weakness, fever, repeated infections, or coagulopathy, a complete blood count is recommended.
Suicide: According to reports, suicides, suicide attempts, suicidal ideation and behavior have occurred in patients treated with antiepileptic drugs (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic drugs showed a slight increase in the risk of suicidal thoughts and behavior. The mechanism of this risk is unclear. Therefore, patients should be monitored for signs of depression and/or suicidal thoughts and behavior, and appropriate treatment should be considered. If there are signs of depression and/or suicidal thoughts or behavior, the patient (and the patient's caregiver) should be advised to seek medical advice.
Pediatric population: The tablet formula is not suitable for infants and children under 6 years of age. The data available for children does not indicate an impact on growth and puberty. However, the long-term effects on children's learning, intelligence, growth, endocrine function, puberty, and reproductive potential are unclear.
Adjunct anti-epileptic drugs
Store at a cool temperature (not exceeding 25°C) and dry place, protected from light.